NCT05768932 2026-03-27
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Phase 1 Recruiting
SillaJen, Inc.
National Institutes of Health Clinical Center (CC)
Myeloid Therapeutics
Multitude Therapeutics Inc.
Azaya Therapeutics, Inc.